• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomePatients & FamiliesSupport for Duchenne

Support for Duchenne

Committed to people and their families living with Duchenne

Read our latest community newsletter

Read newsletter
Subscribe

See the latest sevasemten data.

Watch our latest webinar

Learn more about the LYNX and FOX clinical trial for Duchenne

Check eligibility critera

What is Duchenne?

Duchenne muscular dystrophy is a genetic disorder that causes severe and rapid muscle loss and weakness. People living with Duchenne begin to lose their ability to walk without assistance by their early teens and nearly all will require the use of a wheelchair by the time they are in their mid-teens. Currently, there is no cure for Duchenne but there are approved therapies and clinical trials are ongoing. Preserving muscle function is an important part of managing Duchenne muscular dystrophy.

Learn more about Duchenne clinical trials

Watch our 
Muscle Town video

Discover how muscles work (and why they sometimes don’t in Becker and Duchenne muscular dystrophy) their role in our bodies, the proteins involved, and more.

Watch our NSAA video

Learn how the NSAA, or North Star Ambulatory Assessment, is used in clinical research and care to measure functional progression in individuals with Duchenne or Becker.

Resources

Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy (PPMD)

Fights every single battle necessary to end Duchenne. The organization also supports people and families with Becker.

Learn More About PPMD

Jett Foundation

Jett Foundation

Dedicated to funding Duchenne research and direct service programming for families impacted by Duchenne and other neuromuscular disorders.

Learn More About Jett Foundation

Muscular Dystrophy Association (MDA)

Muscular Dystrophy Association (MDA)

Empowers people living with neuromuscular diseases and looks to accelerate research, advance care, and advocate for the support of families living with muscular dystrophy, ALS, and related neuromuscular diseases.

Learn More About MDA

CureDuchenne

Committed to improving the lives of everyone affected by Duchenne through accelerating research to find the cure, improving care and empowering the Duchenne community.

Learn More About CureDuchenne

The Akari Foundation

The Akari Foundation

Educate and empower the Hispanic community about rare diseases, help with resources, awareness, advocacy, and education, entirely in Spanish, specializing in Duchenne muscular dystrophy.

Educar y empoderar a la comunidad hispana sobre enfermedades raras, ayudar con recursos, concientización, defensa y educación, completamente en español, especializándose en distrofia muscular de Duchenne

Learn More About The Akari Foundation

Treat-NMD

TREAT-NMD

A global network of experts in the neuromuscular field. Everyone in the network helps the organization work toward the mission to accelerate the development of effective
treatments; and establish the best in diagnosis and care for people worldwide.

Learn More About TREAT-NMD

How do others live with Duchenne?

Meet the Romito Brothers.

Brothers. Explorers. Gamers.
Living with Duchenne.

  • Read their story
  • Read other stories in Duchenne

What is Sevasemten?

Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced injury in individuals living with rare skeletal muscle disorders, including Becker and Duchenne. Clinical trials for sevasemten are ongoing.

  • Learn more about sevasemten
  • Explore Clinical Trials

Sevasemten is an investigational therapy that has not been approved for use in Becker muscular dystrophy or Duchenne muscular dystrophy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.

Subscribe to our
community newsletter

Sign up to receive educational updates from Edgewise Therapeutics.

Unsubscribe

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts